Biomedical Research Centre, Institute of Nutrition and Food Technology "José Mataix Verdú", Department of Physiology, University of Granada, Avda. del Conocimiento s/n, 18100, Armilla, Granada, Spain.
Biomedical Research Centre, Institute of Nutrition and Food Technology "José Mataix Verdú", Department of Physiology, University of Granada, Avda. del Conocimiento s/n, 18100, Armilla, Granada, Spain; Sport and Health Research Centre, University of Granada, C/. Menéndez Pelayo 32, 18016, Armilla, Granada, Spain.
Food Chem Toxicol. 2020 Dec;146:111820. doi: 10.1016/j.fct.2020.111820. Epub 2020 Oct 17.
Doxorubicin (DOX), or adriamycin, is an anthracycline antineoplastic drug widely used in the chemotherapy of a large variety of cancers due to its potency and action spectrum. However, its use is limited by the toxicity on healthy cells and its acute and chronic side effects. One of the developed strategies to attenuate DOX toxicity is the combined therapy with bioactive compounds such as flavonoids. This review embraces the role of flavonoids on DOX treatment side effects. Protective properties of some flavonoidss against DOX toxicity have been investigated and observed mainly in heart but also in liver, kidney, brain, testis or bone marrow. Protective mechanisms involve reduction of oxidative stress by decrease of ROS levels and/or increase antioxidant defenses and interferences with autophagy, apoptosis and inflammation. Studies in cancer cells have reported that the anticancer activity of DOX was not compromised by the flavonoids. Moreover, some of them increased DOX efficiency as anti-cancer drug even in multidrug resistant cells.
多柔比星(DOX),又称阿霉素,是一种蒽环类抗肿瘤药物,由于其效力和作用谱,广泛用于多种癌症的化疗。然而,由于其对健康细胞的毒性以及急性和慢性副作用,其应用受到限制。减轻 DOX 毒性的一种策略是与生物活性化合物(如类黄酮)联合治疗。本综述探讨了类黄酮在 DOX 治疗副作用方面的作用。已经研究了一些类黄酮对 DOX 毒性的保护作用,主要在心脏中观察到,但也在肝脏、肾脏、大脑、睾丸或骨髓中观察到。保护机制包括通过降低 ROS 水平和/或增加抗氧化防御来减少氧化应激,以及干扰自噬、细胞凋亡和炎症。在癌细胞中的研究表明,类黄酮不会影响 DOX 的抗癌活性。此外,其中一些类黄酮作为抗癌药物增加了 DOX 的效率,即使在多药耐药细胞中也是如此。
Food Chem Toxicol. 2020-12
Toxicol Lett. 1997-6-16
In Silico Pharmacol. 2025-3-17